Hims & Hers Health, Inc. (HIMS)
| Market Cap | 3.70B -54.5% |
| Revenue (ttm) | 2.21B +78.0% |
| Net Income | 133.79M +32.1% |
| EPS | 0.54 +20.8% |
| Shares Out | 227.65M |
| PE Ratio | 30.31 |
| Forward PE | 30.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,434,428 |
| Open | 16.30 |
| Previous Close | 16.30 |
| Day's Range | 15.79 - 16.92 |
| 52-Week Range | 15.63 - 72.98 |
| Beta | 2.47 |
| Analysts | Hold |
| Price Target | 38.41 (+136.08%) |
| Earnings Date | Feb 23, 2026 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $38.41, which is an increase of 136.08% from the latest price.
News
3 Once-In-A-Decade REIT Opportunities To Win Big
AI is crushing digital businesses, and capital is starting to rotate out of tech. Meanwhile, many REITs trade at 30% discounts to NAV with ~5% yields. We highlight three anti-AI real asset plays that ...
Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More
Traders targeting heavily shorted stocks are looking to play one of two sides: betting on a company's downfall or hunting for a short squeeze.
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows
Hedge fund bets against Hims & Hers Health hit their highest in at least a year in January, just before the online telehealth firm clashed with Novo Nordisk over its cut-price weight-loss pill, accord...
A Historic Opportunity For Dividend Investors To Win Big
AI panic crushed SaaS and dragged down BDCs and asset managers. Trading at steep discounts and high dividend yields, we think that this is a historic opportunity. We explain why the market got it wron...
US could take action including fines against Hims after brief Wegovy copy launch
The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill,...
Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing
Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg's Katie Greifeld to discuss GLP-1 supply, pricing and the company's lawsuit a...
Novo says it's suing Hims to stop obesity drug copycats
Novo Nordisk Chief Executive Officer Maziar Mike Doustdar says it's suing Hims & Hers for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegov...
HIMS Selloff Creates De-Risked Entry
HIMS Selloff Creates De-Risked Entry
Why Cheaper GLP-1 Drugs Are Facing Legal Battles
The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and risi...
Novo Says It's Suing Hims to Halt Obesity Drug Copycats
Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it's suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hi...
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade)
Downgrading Hims & Hers Health, Inc. to Hold as the GLP-1 downside catalysts feel very real now. The FDA signaled new limits on non-approved compounded GLP-1 APIs being mass-marketed, and it explicitl...
Novo Nordisk opens new front with patent suit over Hims' Wegovy copies
Novo Nordisk's U.S. patent lawsuit against Hims & Hers , filed on Monday, marks a new front in the Danish pharmaceutical drugmaker's campaign against companies selling compounded versions of its block...
Why Hims Stock Slid 40% In A Month?
There are two words that can cause a stock to plummet quicker than one can utter semaglutide: FDA warning. This is precisely what transpired with Hims & Hers Health Inc's shares, as Hims & Hers stock ...
Hims & Hers Health: Don't Fall For The Hysteria
Hims & Hers Health trades at yearly lows amid market hysteria over compounded oral Wegovy and regulatory scrutiny. The online health platform is not a GLP-1-centric company; weight-loss sales are fore...
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm.
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug market
The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market.
FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast
• Hims & Hers Health stock is at significant support. What's pressuring HIMS?
Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War
Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much uncertainty.
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn
Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.
Hims & Hers is scrapping its plan for a knockoff Wegovy weight-loss pill. Here's why
Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug Ad...
HIMS Slides 25% After NVO Sues Company Over Generic GLP-1 Pills
Legal issues hits Hims & Hers (HIMS). Novo Nordisk (NVO) filed a lawsuit against the company over allegedly selling unapproved Wegovy and Ozempic weight loss drugs.
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pills, injections
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker's new Wegovy obesity pill and injections in the U.S. CNBC'...
Hims & Hers Stops Selling Wegovy Copycat Weight-Loss Pill
Novo Nordisk A/S shares rose after Hims & Hers Health Inc. agreed to stop selling a copycat version of the new Wegovy weight-loss pill following US government threats to crack down on knockoffs. Bloom...
Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs
Novo Nordisk A/S (NYSE: NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE: HIMS) for infringing U.S. Patent 8,129,343 with Hims' compounded semaglutide produ...
Dr. Scott Gottlieb on Novo Nordisk vs. Hims & Hers: We have a drug approval process for a reason
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the fight between Novo Nordisk and Hims & Hers over GLP-1 drugs, immunization policies in the U.S., and more.